Storage evidence belongs to an exact product. FDA’s briefing discusses peptide sensitivity and supplier-reported figures, not an FDA-approved BPC-157 dispensing label [1]. A manufacturer’s claim, research protocol and approved label are different kinds of information.
No general product-independent rule is established
Approved products have reviewed labels; compounded products may have pharmacy instructions; investigational products have protocol-specific handling controls. None of those facts establishes a universal rule for an unfamiliar product called BPC-157.
FDA’s briefing found no approved product in its international search [1]. That finding should not be turned into a claim that no one has ever studied stability or that every handling instruction is necessarily invented. It does mean there is no approved label to borrow. Clinical outcomes are covered in the BPC-157 evidence review.
A supplier figure is not a universal product instruction
A general online shelf-life claim may omit ingredient identity, salt, concentration, solvent, container, manufacturing controls or the tests used to establish an endpoint. Those omissions prevent transfer of a storage figure to a different formulation. Disagreement alone also does not identify which figure is valid.
Even FDA had to rely on sellers. The storage figures in FDA's own review are cited to two peptide suppliers' product web pages, not to a stability study [1].
| Source | What it is | Is it an official storage instruction? |
|---|---|---|
| FDA briefing, July 2026 [1] | The regulator's review of a nominated substance | No. It is a stability warning, with figures cited to supplier pages |
| Seller listings | Shops selling research vials | No |
| Blogs and forums | Secondary advice that may omit product-specific evidence | No |
| FDA-approved drug label | Does not exist for BPC-157 | Not applicable |
| Investigational handling protocol | Applies to the exact authorized study product | Does not validate a retail product |
What FDA's 2026 review says about stability
FDA reviewed BPC-157 because it had been nominated for the list of substances pharmacies may compound. Its stability section reports, from supplier sources, that the freeze-dried powder should be kept dry and frozen:
FDA explains that formulation, process and environmental conditions—including pH, heat, concentration, impurities and excipients—can change peptide aggregation and degradation [1]. This is a reason for product-specific stability testing, not a ready-made storage schedule.
The review adds that significant amounts of aggregates can form in formulated products, "especially during storage or when exposed to stress conditions" [1]. Its overall conclusion is that BPC-157 is "not well-characterized" physically and chemically.
Why storage is a safety question, not just a potency question
A peptide that breaks down may simply stop working. FDA's concern goes further. Aggregation, where peptide chains clump into larger particles, is a known risk factor for immune reactions [1].
FDA identifies potential immunogenicity concerns for proposed injected and nasal products, amplified by aggregation or impurities; its review did not identify a formal product immunogenicity assessment [1]. This is a potential risk, not a quantified reaction rate. See the safety review.
"Store refrigerated" on a vial proves nothing about what is inside
FDA found several salts and derivatives, including different active molecules, sold under the same "BPC-157" name [1]. It also found that most certificates of analysis for BPC-157 report only a purity figure, with nothing on impurity limits [1].
So a cold-chain sticker on an unregulated vial can't tell you what molecule is in it, how much, or what else came with it. Good storage only protects what was there to begin with.
What a regulated product would look like
A usable stability claim identifies the exact formulation and container and is supported by appropriate testing. A general purity percentage does not establish sterility, potency throughout storage or every relevant impurity. Routine commercial eligibility and authorized investigational use are separate legal questions [1].
An advisory opinion or pending policy review cannot supply storage instructions for a product. Current approval and access questions are covered in FDA status and legal access. Keep those questions separate from a laboratory measurement of chemical stability.
If you already have BPC-157
Don't treat a seller's storage claim as a sign of safety. If you've had a reaction after using BPC-157, tell a clinician exactly what you took. You can also report it to FDA through MedWatch, its adverse-event reporting program [2].